Literature DB >> 27270513

Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis.

B Trilling1, E Cotte, D Vaudoyer, S Isaac, E Piaton, C Maurice, O Glehen, G Passot.   

Abstract

BACKGROUND: Intraperitoneal-free cancer cells are considered as an important prognostic tool in gastric and ovarian cancer. However, their significance in colorectal cancer remains more controversial.
OBJECTIVE: This study aimed to determine the role of intraperitoneal-free cancer cells as a prognostic tool in the outcome in colorectal peritoneal carcinomatosis treated with curative intent by complete cytoreductive surgery.
DESIGN: This study is an analysis of a prospectively maintained database. PATIENTS: Between 1991 and 2012, all patients treated in a single institution for colorectal peritoneal carcinomatosis by complete cytoreductive surgery with peritoneal cytology available were evaluated. Peritoneal cytology was stained in the conventional way (May Grumwald Giemsa).
RESULTS: Among a population of 162 patients treated for colorectal peritoneal carcinomatosis by complete cytoreductive surgery, 38 presented positive intraperitoneal-free cancer cells (23.5%). Systemic chemotherapy was administered to 135 patients (85%) during the preoperative course. Median follow-up was 34.5 months. Median overall survival was 19 and 44 months for positive and negative intraperitoneal-free cancer cells (p = 0.018). In multivariate analysis, Peritoneal Carcinomatosis Index and positive intraperitoneal-free cancer cells were significant prognostic factors of overall survival (HR, 2.3 (1.18-4.52), p = 0.014; HR, 1.9 (1.08-3.38), p = 0.027). LIMITATIONS: Retrospective analysis and the long period were limitations of study.
CONCLUSION: Along with the Peritoneal Carcinomatosis Index, intraperitoneal-free cancer cells are a strong prognostic factor for patients treated with curative intent for colorectal peritoneal carcinomatosis by complete cytoreductive surgery. The presence of intraperitoneal-free cancer cells should lead to the consideration of different treatment strategies such as extensive intraperitoneal lavage, targeted intraperitoneal therapies, or repeated intraperitoneal chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270513     DOI: 10.1097/DCR.0000000000000589

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

Review 1.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 2.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

3.  CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies.

Authors:  Lin Deng; Shikong Guo; Hong Li; Xianghui You; Yang Song; Haichuan Su
Journal:  Cancer Manag Res       Date:  2020-10-22       Impact factor: 3.989

4.  Conventional peritoneal cytology lacks the prognostic significance of detecting local or peritoneal recurrence in colorectal cancer: An Egyptian experience.

Authors:  Mohamed Shalaby; Tarek S El Baradie; Mohamed Salama; Hebat A M Shaaban; Rasha M Allam; Ehab O A Hafiz; Mohamed Aly Abdelhamed; Amr Attia
Journal:  JGH Open       Date:  2020-12-29

5.  Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  Irene López-Rojo; Susana Olmedillas-López; Pedro Villarejo Campos; Víctor Domínguez Prieto; Javier Barambio Buendía; Delia Cortés Guiral; Mariano García-Arranz; Damián García-Olmo
Journal:  Ther Adv Med Oncol       Date:  2020-12-18       Impact factor: 8.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.